Immunovant PT receives Investment Bank Analyst Rating Update
Immunovant, Inc. (IMVT) reported Q2 EPS of ($0.41), $0.04 worse than the analyst estimate of ($0.37).
Investing.com – U.S. stocks were mixed after the close on Monday, as gains in the Utilities, Consumer Goods and Telecoms sectors led shares higher while losses in the Basic...
Small-cap stocks can offer big returns quickly, especially when the economy is rebounding from a slowdown. This is because businesses witness robust earnings growth when the...
Immunovant (NASDAQ:IMVT), Inc. IMVT reported a net loss of 35 cents per share in the second quarter of fiscal 2022 (ended Sep 30, 2021), wider than the Zacks Consensus Estimate of...
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
|Average||13.00 (-9.47% Downside)|
|No. of Analysts||11|